No Data
Taean Kang (301263.SZ): Currently, there is no business or product in the field of assisted reproduction.
Gelonghui November 4th | Taien Kang (301263.SZ) stated on the investor interaction platform that the company is paying attention to the field of assisted reproduction, but currently does not have any business or products in the field of assisted reproduction.
Guangdong Taienkang Pharmaceutical's (SZSE:301263) Anemic Earnings Might Be Worse Than You Think
Taien Health (301263.SZ): Repurchase completed, cumulatively spent 38.9869 million yuan to repurchase 1.9851 million shares.
Gelonghui November 1st | Taencon (301263.SZ) announced that as of November 1, 2024, the company has repurchased a total of 1.985118 million shares through the Shenzhen Stock Exchange trading system through centralized bidding trading, accounting for 0.4665% of the company's total share capital. The highest price of the repurchase transaction is 20.12 yuan/share, the lowest price is 18.56 yuan/share, and the total amount of funds paid is RMB 38.9869 million (excluding transaction costs). At this point, the term for the company's repurchase of shares has expired, and the repurchase plan has been fully implemented.
Taikang (301263.SZ): The phase II clinical trial protocol of CKBA ointment has been completed for subject enrollment.
Tiankang (301263.SZ) announced that the company's controlling subsidiary Jiangsu Bochuangyuan Biomedical Technology Co., Ltd. (简...
Taienkang: Report for the third quarter of 2024
Taiankang (301263.SZ): net income of 0.116 billion yuan in the first three quarters, a year-on-year decrease of 17.97%.
On October 28th, Tenco (301263.SZ) released the third quarter report for 2024, with the company achieving revenue of 0.572 billion yuan in the first three quarters, a 1.50% year-on-year decrease; net income attributable to shareholders of the listed company was 0.116 billion yuan, a 17.97% year-on-year decrease; net profit attributable to shareholders of the listed company excluding non-recurring gains and losses was 0.114 billion yuan, a 13.58% year-on-year decrease; basic earnings per share of 0.27 yuan.
Cautious Investors Not Rewarding Guangdong Taienkang Pharmaceutical Co., Ltd.'s (SZSE:301263) Performance CompletelyNo Data
No Data
